查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840678

神经血管设备市场（按产品类型、适应症、最终用户和分销管道）—2025-2032 年全球预测

Neurovascular Devices Market by Product Type, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经血管设备市场将成长至 61.8 亿美元，复合年增长率为 7.56%。

主要市场统计数据
基准年2024年 34.4亿美元
预计2025年 37.1亿美元
预测年份：2032年 61.8亿美元
复合年增长率（%） 7.56%

对神经血管设备生态系统进行清晰的执行概述，使临床创新与商业性和监管标准保持一致

神经血管器材领域正处于快速临床创新与日益严格的医疗体系审查的交汇点，要求高阶主管在做出策略决策时拥有清晰的认知。器械设计、影像整合和围手术期护理方面的进步正在再形成临床医生的期望，并不断扩展手术适应症，而付款方和采购负责人也日益要求可验证的疗效和成本效益。如今，相关人员需要简洁、循证且全面的讯息，将技术能力与临床终点和商业性可行性联繫起来。

围绕微创方法和影像引导介入的临床发展势头正在提高设备性能和操作人员培训的标准。同时，医疗保健提供者面临着优化患者吞吐量的压力，并透过显着改善发病率和住院时间来证明资本和耗材支出的合理性。因此，投资者和企业负责人正在寻求能够将手术创新转化为永续应用路径的分析。本引言将临床、监管和商业因素结合起来，建构了更广泛的报告框架，这些因素将决定哪些技术和提供者将在神经血管生态系统中获得持久的吸引力。

后续章节重点介绍了变革的关键驱动因素、影响采购和报销决策的细分模式，以及影响市场进入和扩张的地理和竞争动态。本报告旨在为领导团队提供清晰的叙述，指南优先排序和投资决策。

技术成熟度、监管期望和程序标准化如何重塑采用路径和竞争优势

由于三大力量的汇聚：技术成熟度、操作标准化以及支付方预期的转变，神经血管器械领域正在经历深刻变化。器械迭代越来越受到真实世界性能数据和计算模型的影响，从而加速了从一次性原型到临床稳健平台的转变。操作流程的改善和标准化训练路径正在降低患者治疗结果的差异性，并推动其从小众转诊中心向更广泛的医疗机构推广应用。

监管机构对临床证据和上市后监管的期望也在不断变化，鼓励製造商将数据生成功能纳入设备生命週期。相关人员正在寻求能够显着改善疗效并简化工作流程的整合解决方案。此外，供应链弹性和製造扩充性已成为策略重点，领导者正在投资试剂筹资策略和双重采购，以减轻外部衝击。

因此，市场差异化日益受到临床证据、程序效率以及向付款人和医院采购委员会展示价值的能力的驱动。这种转变对产品开发蓝图、商业化模式和合作策略产生了实际的影响，迫使企业根据临床实践模式和报销现实情况重新调整其研发重点和市场进入时机。

近期关税对供应链、采购和伙伴关係的累积影响正在重塑采购和定价策略

近期的关税措施和贸易政策调整，给神经血管器械供应链带来了明显的压力点，製造商和供应商必须积极应对。影响原料进口、零件和成品器械的关税增加了一些製造商的采购成本，促使其采取在岸製造和策略采购安排。为此，一些製造商正在重新审视供应商合同，并探索近岸外包和区域製造中心，以保持利润的完整性和供应的连续性。

对于医院和门诊中心而言，采购成本的上升给资本配置决策带来了压力，并加剧了对设备利用率和每个成本指标的审查。因此，采购部门正在加强竞争性竞标，延长供应商资格审查週期，而临床团队则面临压力，需要提供临床疗效改善和下游成本降低的证据来证明设备选择的合理性。同时，关税也凸显了灵活分销管道的重要性，企业纷纷在直销、第三方分销商和数位采购平台之间寻求多元化发展，以维持议价能力。

重要的是，政策环境也影响策略伙伴关係和许可安排。在受关税影响的司法管辖区之外拥有製造地的公司享有相对的物流优势，而其他公司则正在加速迁移协议和区域许可，以保持市场进入。展望未来，积极优化采购、调整定价策略并加强区域物流的相关人员将更有能力吸收政策引发的成本波动并保持供应可靠性。

详细的細項分析揭示了产品架构、临床适应症、护理环境和通路如何推动不同的采用和采购行为

神经血管器材产业的细分揭示了清晰的采用路径和与产品类型、临床指征、最终用户和分销管道相关的不同商业性要求。产品类型包括血流改道装置、微导管、神经血管线圈和神经血管支架，每种产品都有其独特的工程限制和临床效用。在血流改道装置领域，管道栓塞平台、丝质结构和 Surpass 架构系统等装置在输送能力和管壁适形性方面相互竞争，而微导管则依靠亲水性和 PTFE 等涂层在曲折的脑血管中实现最佳导航。线圈技术范围从裸金属到生物活性和水凝胶增强类型，旨在提高动脉瘤闭塞的耐久性。支架系列分为编织型和雷射切割型，以平衡径向强度与灵活性和血管适形性。

有有效策略的公司正在将支架应用于多个领域，包括动静脉畸形的治疗、颅内动脉瘤的治疗、颅内狭窄的治疗以及缺血性中风的治疗。同时，对于颅内动脉瘤的治疗，血管内卷取、血流转移策略和支架辅助栓塞之间的器械选择受到动脉瘤形态和临床风险状况的影响。颅内狭窄的治疗主要依赖球囊血管成形术和置入术，而缺血性中风的治疗则涉及动脉内血栓溶解和机械血栓切除术，每种治疗都需要特定的器械相容性和影像学工作流程。

终端使用者细分揭示了门诊手术中心、医院和专科诊所之间购买行为的差异。门诊中心的隶属关係各不相同；医院的范围从初级区域医疗机构到拥有复杂介入神经放射学计画的三级医疗中心；专科诊所包括介入放射科和神经内科诊所，也可能充当转诊中心。分销管道也对市场进入和服务模式产生重大影响，包括透过现场代理商或机构合约进行的直销、透过电子商务平台或製造商入口网站的线上销售，以及跨零售和批发网路的第三方经销商。要应对这种多层次的细分，需要针对每个相关人员定制价值提案，并将设备功能与程序要求、报销实际情况和采购模式结合。

跨区域监管、报销和製造动态将决定世界主要医疗保健地区之间的差异化商业策略

区域动态对神经血管器材的监管格局、报销框架和製造策略有着巨大的影响，美洲、欧洲、中东和非洲以及亚太地区各司法管辖区之间存在显着差异。在美洲，医院系统整合和对真实世界证据的关注正在影响报销讨论，并提升了卫生经济学在采购谈判中的重要性。该地区的医疗保健提供者通常优先考虑那些能够展现操作效率并有可能减少住院时间的技术，这反过来又会影响商业讯息通讯和临床试验设计。

在欧洲、中东和非洲，监管协调工作和多样化的报销环境既带来了机会，也带来了复杂性。製造商必须应对错综复杂的国家医疗保健体系和付款人要求，同时利用集中采购机会进行跨国竞标。同时，亚太地区由于其诊疗量迅速增长且监管成熟度参差不齐，需要製定兼顾成本竞争力和可扩展临床教育计画的策略。在地化生产和有针对性的临床合作已成为该地区应对价格敏感性并加速应用的常用策略。

在所有地区，跨境物流、智慧财产权考量以及在地培训能力都在影响参与策略和伙伴关係模式。早期投资于特定区域监管规划、本地化临床证据产生和供应链冗余的利益相关人员更有可能获得更可靠的市场进入，并促进更深入的临床医生参与，从而提高在不同地域的医疗保健生态系统中持续采用的可能性。

产品差异化、策略联盟和卓越营运如何塑造竞争优势和长期临床医生偏好

活跃于神经血管器材领域的公司之间的竞争动态主要围绕着产品差异化、实证医学证据产生以及拓展核心技术临床效用的策略联盟。老牌器材製造商通常利用其广泛的产品组合，提供包含仪器、影像处理软体和培训服务的捆绑式解决方案，从而降低寻求整合服务的医院系统的采用门槛。相较之下，专业公司和新兴企业通常专注于狭窄的创新方向，例如新型血流路径导流支架或先进的线圈化学技术，以建立临床验证点并吸引合作或收购兴趣。

策略交易、授权协议和共同开发伙伴关係是扩大技术规模、加快市场准入的有效途径，尤其是在监管和临床检验週期较长的情况下。与领先的介入神经放射学中心合作设计手术流程的公司可以获得早期采用和真实世界的数据流，从而支持付款人谈判。同样，与影像和软体供应商合作，使医疗设备製造商能够将分析和结果追踪纳入其价值提案。

投资于製造品质系统、强大的上市后监管和响应迅速的现场支援的公司更有可能赢得临床医生的信任并维护与医疗机构的合约。为了应对采购的复杂性并展现对共用患者结果目标的承诺，越来越多的公司开始采用定价灵活性、捆绑销售和基本契约。最终，那些将技术差异化与清晰的证据产生路径和可靠的服务交付相结合的公司将最有可能获得长期的临床青睐。

为医疗设备製造商和医疗保健提供者提供实用的策略手册，以协调临床证据、製造弹性和定製商业化，从而加速采用

产业领导者应采取多管齐下的策略，将研发重点与可证明的临床价值结合，同时增强供应链的韧性和商业性敏捷性。首先，优先考虑旨在解答付款人和医院决策者关于疗效和抵消成本问题的临床证据项目，确保研究终点符合现实世界的决策标准。其次，将资料收集和分析功能嵌入到设备和上市后註册中，以获得持续的绩效洞察，支持报销讨论和迭代产品改进。

第三，多元化您的製造和采购布局，以缓解政策和物流中断的影响，并考虑区域伙伴关係和授权许可，以保持市场连续性。第四，透过为门诊中心、三级医院和专科诊所提供差异化的价值提案，使其反映各自的临床工作流程和采购限制，从而使您的市场策略与最终用户细分保持一致。第五，扩展您的商业模式，包括灵活的合约、捆绑产品和培训伙伴关係，以减少采用摩擦，并协调供应商和製造商之间的奖励。

最后，我们致力于与影像和软体供应商、临床领导者以及分销合作伙伴建立合作关係，以建立全面的手术解决方案。透过将有针对性的临床专案与富有弹性的营运和自适应商业化相结合，组织可以加速应用，并向整个神经血管生态系统的相关人员展示长期价值。

严格的混合方法研究途径，结合专家访谈、监管分析和临床证据综合来支持策略决策

本报告所依据的研究结合了与临床专家、采购主管和设备管理人员的初步定性交流，以及对监管指南和同行评审临床文献的系统分析。主要访谈对象包括介入神经科、介入神经放射学放射科医生、医院采购经理和产品开发主管，重点关注已发表资讯来源中未一致描述的实践操作和决策因素。调查团队将访谈结果与监管备案文件、设备标籤资讯和临床註册结果进行交叉比对，以检验观察到的趋势并识别新出现的应用障碍。

二次研究包括对临床试验、系统综述和卫生技术评估报告进行结构化审查，以确定设备在适应症范围内的临床应用背景。供应链分析利用公开的贸易数据、製造足迹和企业资料，绘製关税和采购的潜在影响点。此外，该调查方法结合了情境规划，以考虑供应链、报销和法规的结合如何影响采购动态，但未提供具体的市场规模或预测。

整个调查方法都强调可重复性和透明度。访谈方案和纳入标准均已标准化，资料来源也进行了交叉引用以减少偏差。定性洞察与文献检验相结合，提供了坚实的依证，旨在为神经血管器械领域的相关人员提供策略和产业计画的参考。

简洁的综合策略要点，协调创新、证据生成和营运弹性，确保持久的临床应用

本分析中提出的累积见解明确指出，相关人员必须迅速且周到地采取行动。器械设计和操作实践的技术进步正在拓展临床选择，但其应用取决于可证实的疗效、清晰的定价和可靠的供应。监管预期和付款人审查日益凸显了整合证据策略和上市后资料收集的重要性，而贸易政策的变化则强化了多元化采购和区域製造策略的价值。

对于决策者来说，将产品开发与临床医生、付款人和医院采购方的资讯需求结合才是未来的发展方向。这意味着要优先考虑能够产生可操作结果资料的临床项目，设计能够减少采购摩擦的商业模式，并投资于支援培训和设备生命週期管理的服务能力。将技术差异化与营运韧性和实证商业化相结合的组织，将创造可持续的优势，并为临床选择提供清晰的路径。

总而言之，神经血管器材的市场格局蕴藏着巨大的机会，但要抓住机会，需要在研发、监管、生产和上市执行方面製定协调一致的策略。相关人员如果立即采取行动，加强证据产生、供应链灵活性和商业性参与协调，将最有可能将创新转化为持续的临床和商业性成功。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用下一代生物可吸收支架减少长期血管炎症
  • 将人工智慧和机器学习融入神经血管介入规划
  • 开发可进入远端脑血管的微导管技术
  • 扩大大血管急性缺血性脑中风血栓除去装置的适应症
  • 引入聚合物涂层弹簧圈，以提高复杂解剖结构中动脉瘤闭塞的耐久性
  • 扩展远端医疗功能，实现复杂神经介入手术的远端监控
  • 患者专用 3D 列印血管模型的进展可优化手术结果

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章神经血管设备市场（依产品类型）

  • 导流装置
    • 管道栓塞装置
    • 丝绸装置
    • 超越装置
  • 微导管
    • 亲水涂层
    • PTFE涂层
  • 神经血管线圈
    • 裸露金属线圈
    • 生物活性线圈
    • 水凝胶线圈
  • 神经血管支架
    • 编织支架
    • 雷射切割支架

第九章神经血管设备市场（按适应症）

  • 动静脉畸形
    • 黏性栓塞剂
    • 缟玛瑙
  • 颅内动脉瘤
    • 血管内弹簧圈栓塞术
    • 流量转换
    • 支架辅助弹簧圈栓塞术
  • 颅内狭窄
    • 球囊血管成形术
    • 支架置入术
  • 缺血性中风
    • 动脉内血栓溶解
    • 机械血栓切除术

第 10 章神经血管设备市场（依最终用户）

  • 门诊手术中心
    • 医院相关中心
    • 独立中心
  • 医院
    • 基层医院
    • 三级医疗机构
  • 专科诊所
    • 介入放射科诊所
    • 神经科诊所

第 11 章神经血管设备市场（依通路）

  • 直销
    • 现场负责人
    • 医院合约
  • 网上销售
    • 电商平台
    • 製造商网站
  • 第三方经销商
    • 零售
    • 批发商

第 12 章神经血管设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章神经血管设备市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章神经血管设备市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Medtronic plc
    • Stryker Corporation
    • Johnson & Johnson Services, Inc.
    • Penumbra, Inc.
    • Terumo Corporation
    • Boston Scientific Corporation
    • MicroPort Scientific Corporation
    • Cordis LLC
    • Siemens Healthineers AG
    • Asahi Intecc Co., Ltd.
Product Code: MRR-0360AB17E1FE

The Neurovascular Devices Market is projected to grow by USD 6.18 billion at a CAGR of 7.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.44 billion
Estimated Year [2025] USD 3.71 billion
Forecast Year [2032] USD 6.18 billion
CAGR (%) 7.56%

A clear executive overview of the neurovascular devices ecosystem that aligns clinical innovation with commercial and regulatory decision criteria

The neurovascular devices domain sits at the intersection of rapid clinical innovation and heightened health system scrutiny, demanding clarity for executives making strategic choices. Advances in device design, imaging integration, and periprocedural care have reshaped clinician expectations and broadened procedural indications, while payers and procurement officers increasingly demand demonstrable outcomes and cost-effectiveness. Stakeholders now require concise, evidence-based syntheses that link technological capabilities to clinical endpoints and commercial viability.

Clinical momentum around minimally invasive approaches and imaging-guided interventions has raised the bar for device performance and operator training. Concurrently, healthcare providers face pressure to optimize patient throughput and justify capital and consumable expenditures through measurable improvements in morbidity and length of stay. Investors and corporate strategists are therefore looking for analyses that translate procedural innovation into sustainable adoption pathways. This introduction frames the broader report by aligning clinical, regulatory, and commercial vectors that will determine which technologies and providers gain enduring traction in the neurovascular ecosystem.

Throughout the subsequent sections, the report zeroes in on the major drivers of change, the segmentation patterns that influence procurement and reimbursement decisions, and the regional and competitive dynamics that shape market entry and expansion. The aim is to provide leadership teams with a coherent narrative that guides prioritization and investment decisions in a complex, fast-evolving field.

How technological maturation, regulatory expectations, and procedural standardization are reshaping adoption pathways and competitive advantages

The landscape for neurovascular devices is experiencing transformative shifts driven by three converging forces: technological maturation, procedural standardization, and shifting payer expectations. Device iterations are increasingly informed by real-world performance data and computational modeling, which in turn accelerate the transition from single-use prototypes to clinically robust platforms. Procedural refinements and standardized training pathways are reducing variability in patient outcomes, pushing adoption from niche referral centers toward broader institutional settings.

Regulatory authorities are also evolving their expectations for clinical evidence and post-market surveillance, prompting manufacturers to embed data-generation capabilities into device lifecycles. This regulatory pressure is catalyzing partnerships between device makers and imaging or software vendors, as stakeholders seek integrated solutions that offer measurable outcome improvements and streamlined workflows. In addition, supply chain resilience and manufacturing scalability have become strategic priorities; leaders are investing in reagent sourcing strategies and dual-sourcing to mitigate external shocks.

The cumulative effect is a marketplace where differentiation increasingly rests on clinical evidence, procedural efficiency, and the capacity to demonstrate value to payers and hospital procurement committees. These shifts have practical implications for product development roadmaps, commercialization models, and collaboration strategies, and they necessitate that companies recalibrate R&D priorities and market entry timing to align with both clinical practice patterns and reimbursement realities.

The cumulative supply chain, procurement, and partnership implications of recent tariff activity that are reshaping sourcing and pricing strategies

Recent tariff measures and trade policy adjustments have created discernible pressure points across the neurovascular devices supply chain that manufacturers and providers must navigate. Tariffs influencing raw material imports, componentry, and finished devices have raised procurement costs for some manufacturers and incentivized onshore manufacturing and strategic sourcing arrangements. In response, several manufacturers have re-evaluated supplier contracts and explored nearshoring and regional manufacturing hubs to preserve margin integrity and supply continuity.

For hospitals and ambulatory centers, the pass-through effects of increased procurement costs have pressured capital allocation decisions and brought greater scrutiny to device utilization and cost-per-case metrics. As a result, purchasing departments are intensifying competitive bidding and lengthening vendor qualification cycles, while clinical teams are being asked to justify device selection through evidence demonstrating improved clinical outcomes or reduced downstream costs. At the same time, tariffs have heightened the importance of flexible distribution channels; organizations are diversifying between direct sales, third-party distributors, and digital procurement platforms to retain negotiating leverage.

Importantly, the policy environment has also influenced strategic partnerships and licensing arrangements. Firms with manufacturing footprints outside tariff-impacted jurisdictions have gained relative logistical advantages, while others have accelerated transfer agreements and regional licensing to maintain market access. Moving forward, stakeholders who proactively optimize sourcing, adapt pricing strategies, and strengthen regional logistics will be better positioned to absorb policy-induced cost variability and sustain supply reliability.

In-depth segmentation analysis revealing how product architectures, clinical indications, care settings, and distribution routes drive distinct adoption and procurement behaviors

Segmentation within the neurovascular devices space reveals distinct pathways to adoption and distinct commercial imperatives tied to product type, clinical indication, end user, and distribution channel. Product typology spans flow diversion devices, microcatheters, neurovascular coils, and neurovascular stents, each carrying unique engineering constraints and clinical utility. Within flow diversion, devices like pipeline embolization platforms, silk-style constructs, and surpass-architecture systems compete on deliverability and wall apposition, while microcatheters rely on coatings such as hydrophilic and PTFE to optimize navigation through tortuous cerebral vasculature. Coil technologies range from bare metal to bioactive and hydrogel-enhanced variants that aim to improve aneurysm occlusion durability. Stent families, divided between braided and laser-cut architectures, balance radial strength against flexibility and vessel conformability.

Clinical indication segmentation further differentiates adoption dynamics across arteriovenous malformation interventions, intracranial aneurysm treatments, intracranial stenosis management, and ischemic stroke therapies. AVM interventions pivot on the selection of glue embolic agents versus Onyx-based systems, whereas intracranial aneurysm care involves choices among endovascular coiling, flow diversion strategies, and stent-assisted coiling, with device selection influenced by aneurysm morphology and clinical risk profiles. Intracranial stenosis care leans on balloon angioplasty and stenting techniques, and ischemic stroke pathways include intraarterial thrombolysis and mechanical thrombectomy systems, each demanding specific device compatibilities and imaging workflows.

End-user segmentation highlights differentiated purchasing behaviors across ambulatory surgical centers, hospitals, and specialty clinics. Ambulatory centers vary by affiliation status, hospitals range from primary community facilities to tertiary care centers with complex neurointerventional programs, and specialty clinics encompass interventional radiology and neurology clinics that may act as referral hubs. Distribution channels also cast significant influence on market access and service models, with direct sales supported by field representatives and institutional contracts, online sales through e-commerce platforms and manufacturer web portals, and third-party distributors spanning retail and wholesale networks. Navigating this layered segmentation requires tailored value propositions for each stakeholder, aligning device features with procedural requirements, reimbursement realities, and procurement models.

Cross-regional regulatory, reimbursement, and manufacturing dynamics that determine differentiated commercial strategies across major global healthcare regions

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and manufacturing strategies across the neurovascular devices landscape, with material differences observable between the Americas, Europe, Middle East & Africa, and Asia-Pacific jurisdictions. In the Americas, consolidation in hospital systems and a strong emphasis on real-world evidence are shaping reimbursement discussions and elevating the importance of health economics in procurement conversations. Providers in this region often prioritize technologies that demonstrate procedural efficiency and the potential to reduce length of stay, which in turn affects commercial messaging and clinical trial design.

In Europe, Middle East & Africa, regulatory harmonization efforts and variable reimbursement environments create both opportunities and complexities. Manufacturers must navigate a mosaic of national health systems and payer requirements, while also capitalizing on centralized procurement opportunities for cross-border tenders. Meanwhile, the Asia-Pacific region presents a mix of rapidly expanding procedural volumes and differing regulatory maturation, prompting strategies that balance cost competitiveness with scalable clinical education programs. Localization of manufacturing and targeted clinical partnerships have become common tactics in the region to accelerate adoption while addressing pricing sensitivity.

Across all regions, cross-border logistics, intellectual property considerations, and regional training capabilities inform both entry strategies and partnership models. Stakeholders that invest early in region-specific regulatory planning, localized clinical evidence generation, and supply chain redundancy tend to secure more reliable market access and foster deeper clinician engagement, thereby improving the odds of sustained adoption across geographically diverse healthcare ecosystems.

How product differentiation, strategic alliances, and operational excellence are shaping competitive advantage and long-term clinician preference

Competitive dynamics among companies active in the neurovascular devices sector center on product differentiation, evidence generation, and strategic collaborations that extend the clinical utility of core technologies. Established device manufacturers often leverage broad portfolios to offer bundled solutions that include devices, imaging software, and training services, thereby lowering the barrier to adoption for hospital systems seeking integrated offerings. In contrast, specialized firms and startups typically focus on narrow innovation vectors-such as novel flow diversion scaffolds or advanced coil chemistries-to establish clinical proof points and attract partnership or acquisition interest.

Strategic transactions, licensing agreements, and co-development partnerships are prominent routes to scale technology and accelerate market entry, particularly where regulatory or clinical validation timelines are lengthy. Companies that align with leading neurointerventional centers to co-design procedural workflows gain early adopters and real-world data streams that support payer discussions. Similarly, alliances with imaging and software vendors enable device makers to incorporate analytics and outcome tracking into their value proposition.

Operational excellence remains a differentiator; firms that invest in manufacturing quality systems, robust post-market surveillance, and responsive field support tend to sustain clinician trust and institutional contracts. Pricing flexibility, bundled contracting, and outcomes-based agreements are increasingly employed by companies to address procurement complexity and to demonstrate commitment to shared patient outcome goals. Ultimately, the firms that combine technical differentiation with clear pathways to evidence generation and dependable service delivery will be best positioned to capture long-term clinical preference.

A pragmatic strategic playbook for device makers and providers to align clinical evidence, manufacturing resilience, and tailored commercialization to accelerate adoption

Industry leaders should adopt a multi-pronged strategy that aligns R&D priorities with demonstrable clinical value, while simultaneously reinforcing supply chain resilience and commercial agility. First, prioritize clinical evidence programs that are designed to answer payer and hospital decision-maker questions about outcomes and cost offsets, ensuring that study endpoints map to real-world decision criteria. Second, embed data capture and analytics capabilities into devices and post-market registries to generate ongoing performance insights that support reimbursement discussions and iterative product improvements.

Third, diversify manufacturing and procurement footprints to mitigate policy or logistic disruptions, and consider regional partnerships or licensing to preserve market continuity. Fourth, tailor go-to-market approaches to end-user segmentation by creating differentiated value propositions for ambulatory centers, tertiary hospitals, and specialty clinics that reflect each setting's clinical workflows and purchasing constraints. Fifth, expand commercial models to include flexible contracting, bundled offerings, and training partnerships that reduce adoption friction and align incentives between providers and manufacturers.

Finally, invest in collaborative relationships with imaging and software providers, clinical leaders, and distribution partners to create comprehensive procedural solutions. By coupling targeted clinical programs with resilient operations and adaptive commercialization, organizations can both accelerate adoption and demonstrate long-term value to stakeholders across the neurovascular ecosystem.

A rigorous mixed-methods research approach combining expert interviews, regulatory analysis, and clinical evidence synthesis to support strategic decision-making

The research underpinning this report synthesizes primary qualitative engagement with clinical experts, procurement leaders, and device executives alongside systematic analysis of regulatory guidance and peer-reviewed clinical literature. Primary interviews were conducted with interventional neurologists, neurointerventional radiologists, hospital purchasing managers, and product development leaders to surface operational realities and decision drivers that do not consistently appear in published sources. The research team triangulated interview findings with regulatory filings, device labeling information, and clinical registry outcomes to validate observed trends and to identify emerging adoption barriers.

Secondary research included a structured review of clinical trials, systematic reviews, and health technology assessment reports to establish the clinical context for device usage across indications. Supply chain analysis drew on publicly available trade data, manufacturing footprints, and corporate disclosures to map likely tariff and sourcing exposure points. In addition, the methodology incorporated scenario planning to examine how supply chain, reimbursement, and regulatory permutations could affect procurement dynamics, without projecting specific market sizes or forecasts.

Throughout, the methodology emphasized reproducibility and transparency. Interview protocols and inclusion criteria were standardized, and data sources were cross-referenced to reduce bias. The combination of qualitative insight and document-based verification yields a robust evidence base designed to inform strategy and operational planning for stakeholders engaged in the neurovascular devices domain.

A concise synthesis of strategic imperatives that align innovation, evidence generation, and operational resilience to secure durable clinical adoption

The cumulative insights presented across this analysis paint a clear imperative for stakeholders to act with both speed and deliberation. Technological progress in device design and procedural practice is expanding clinical options, but adoption will hinge on demonstrable outcomes, pricing clarity, and supply reliability. Regulatory expectations and payer scrutiny are elevating the importance of integrated evidence strategies and post-market data capture, while trade policy shifts are reinforcing the value of diversified sourcing and regional manufacturing strategies.

For decision-makers, the path forward requires aligning product development with the information needs of clinicians, payers, and hospital purchasers. This means prioritizing clinical programs that generate actionable outcomes data, designing commercial models that reduce procurement friction, and investing in service capabilities that support training and device lifecycle management. Organizations that combine technical differentiation with operational resilience and evidence-driven commercialization will create durable advantages and clearer pathways to clinical preference.

In sum, the neurovascular devices landscape presents significant opportunity, but realizing that opportunity demands coordinated strategies across R&D, regulatory planning, manufacturing, and go-to-market execution. Stakeholders who act now to shore up evidence generation, supply chain flexibility, and tailored commercial engagement will be best positioned to translate innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of next-generation bioresorbable stents reducing long-term vessel inflammation
  • 5.2. Integration of artificial intelligence and machine learning in neurovascular intervention planning
  • 5.3. Development of microcatheter technologies enabling access to distal cerebral vasculature
  • 5.4. Expansion of thrombectomy device indications to treat large vessel acute ischemic strokes
  • 5.5. Emergence of polymer-coated coils for enhanced aneurysm occlusion durability in complex anatomies
  • 5.6. Growth of telemedicine-enabled remote proctoring for complex neurointerventional procedures
  • 5.7. Advancements in patient-specific 3D-printed vascular models to optimize surgical outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Devices Market, by Product Type

  • 8.1. Flow Diversion Devices
    • 8.1.1. Pipeline Embolization Devices
    • 8.1.2. Silk Devices
    • 8.1.3. Surpass Devices
  • 8.2. Microcatheters
    • 8.2.1. Hydrophilic Coated
    • 8.2.2. PTFE Coated
  • 8.3. Neurovascular Coils
    • 8.3.1. Bare Metal Coils
    • 8.3.2. Bioactive Coils
    • 8.3.3. Hydrogel Coils
  • 8.4. Neurovascular Stents
    • 8.4.1. Braided Stents
    • 8.4.2. Laser Cut Stents

9. Neurovascular Devices Market, by Indication

  • 9.1. Arteriovenous Malformation
    • 9.1.1. Glue Embolic Agents
    • 9.1.2. Onyx
  • 9.2. Intracranial Aneurysm
    • 9.2.1. Endovascular Coiling
    • 9.2.2. Flow Diversion
    • 9.2.3. Stent Assisted Coiling
  • 9.3. Intracranial Stenosis
    • 9.3.1. Balloon Angioplasty
    • 9.3.2. Stenting
  • 9.4. Ischemic Stroke
    • 9.4.1. Intraarterial Thrombolysis
    • 9.4.2. Mechanical Thrombectomy

10. Neurovascular Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital Affiliated Centers
    • 10.1.2. Independent Centers
  • 10.2. Hospitals
    • 10.2.1. Primary Hospitals
    • 10.2.2. Tertiary Care Hospitals
  • 10.3. Specialty Clinics
    • 10.3.1. Interventional Radiology Clinics
    • 10.3.2. Neurology Clinics

11. Neurovascular Devices Market, by Distribution Channel

  • 11.1. Direct Sales
    • 11.1.1. Field Representatives
    • 11.1.2. Hospital Contracts
  • 11.2. Online Sales
    • 11.2.1. E Commerce Platforms
    • 11.2.2. Manufacturer Websites
  • 11.3. Third Party Distributors
    • 11.3.1. Retail Distributors
    • 11.3.2. Wholesale Distributors

12. Neurovascular Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Stryker Corporation
    • 15.3.3. Johnson & Johnson Services, Inc.
    • 15.3.4. Penumbra, Inc.
    • 15.3.5. Terumo Corporation
    • 15.3.6. Boston Scientific Corporation
    • 15.3.7. MicroPort Scientific Corporation
    • 15.3.8. Cordis LLC
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. Asahi Intecc Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS,